Introduction {#Sec1}
============

*Helicobacter pylori* (*H*. *pylori*), a gram-negative bacterium that colonizes the human stomach, has been evolving with humans for tens of thousands of years. Substantial evidence supports a central role for *H*. *pylori* in the pathogenesis of upper gastrointestinal diseases, including peptic ulcer and non-cardia gastric cancer^[@CR1]^. Unlike other developed countries, gastric cancer burden remains high in Japan, where it is the second leading cause of cancer deaths, accounting for annual deaths of approximately 50,000^[@CR2]^. The reason for the lingering high gastric cancer incidence is manifold, but a high prevalence of *H*. *pylori* infection, reportedly as high as 80% among Japanese adults over 40 years old in a 1982 study by Asaka *et al*.^[@CR3]^, appears to be the major contributor. Currently approximately 40% of the Japanese adult population are estimated to be infected with *H*. *pylori* ^[@CR4]^.

Numerous epidemiological studies in Japan have reported the prevalence of *H*. *pylori* infection in various time points and age groups. These findings have shown that the prevalence of *H*. *pylori* infection increases with age^[@CR5]^. This phenomenon is presumably due to a birth-cohort effect, because almost all *H*. *pylori* infection is acquired prior to the age of five, and because the environment during early childhood, such as water supply system, socioeconomic status, household living environment and hygiene habits, is closely associated with *H*. *pylori* infection^[@CR6]^. Given these unique characteristics of *H*. *pylori*, the prevalence by birth year would be a valuable indicator that can reflect the time trends of *H*. *pylori* infection.

Previous studies conducted in the Western population have suggested that gastric cancer, gastric ulcer and duodenal ulcer, the three main *H*. *pylori*-related diseases, exhibit a similar birth cohort pattern, with lower rates observed in subsequent generations^[@CR7]^. A decline in the prevalence of *H*. *pylori* infection in the general population is thought to be the major driving force behind this common pattern, since potent risk factors other than *H*. *pylori* have not been identified. Nevertheless, whether *H*. *pylori* prevalence itself shows a birth-cohort pattern remains to be corroborated. To our knowledge, there is no systematic review or meta-analysis consolidating the data on the prevalence of *H*. *pylori* infection from studies involving Japanese individuals. Therefore, we systematically reviewed the existing literature that presented estimates of the prevalence of *H*. *pylori* infection in the Japanese population. We aimed to derive a robust prevalence estimate of *H*. *pylori* infection by birth year, and to explore the factors that may be associated with between-study variations in *H*. *pylori* infection in our meta-regression analysis. These findings will help to inform gastric cancer screening policies.

Methods {#Sec2}
=======

The PRISMA statement for preferred reporting of systematic reviews and meta-analyses was used as a guide to conduct this study.

Data sources and Search strategy {#Sec3}
--------------------------------

Using the databases of PubMed and EMBASE, we performed a systematic review of the published studies on the prevalence of *H*. *pylori* infection in the Japanese population. The search on PubMed was limited to those studies that were conducted in human and to those that were published from inception to 30 June, 2016 with the following search terms: ("Helicobacter" \[Mesh\] OR "Helicobacter pylori" \[title/abstract\]) AND ("Prevalence" \[Mesh\] OR "prevalence" \[title/abstract\] OR "infection rate") AND ("Japan" \[Mesh\] OR "Japan" \[title/abstract\] OR "Japanese" \[title/abstract\]). Similar strategies were applied in searching published studies in Embase. The search terms used in EMBASE were as follows: ("prevalence"/exp OR "prevalence": ab, ti OR "infection rate"/exp OR "infection rate": ab, ti) AND ("Japan"/exp OR "Japan": ab, ti OR "Japanese": ab, ti) AND ("helicobacter"/exp OR "helicobacter pylori": ab, ti) AND (humans)/lim. To supplement electronic database searches, we also scrutinised the reference lists, and searched for unpublished data by contacting the head of known ongoing study projects in Japan.

Study selection {#Sec4}
---------------

After excluding the duplicate literature from the two databases, we applied the following exclusion criteria: sample size less than 100; no information on time periods during which the study was conducted; review articles; studies published in languages other than English; reports on prevalence without stratifying subjects into different age groups; patients with symptomatic digestive diseases including peptic ulcer, gastric cancer and gastric MALT lymphoma. Studies were eligible for inclusion if they were cross-sectional, case-control (only data in the control groups were extracted), or cohort studies that reported the prevalence and numbers of *H*. *pylori* infection in defined age groups (that is, age of those from whom samples were taken were specified or studies took place in population groups of a known age); or if they reported on the prevalence in any screening setting (such as community-based or hospital-based). We also included baseline data for *H*. *pylori* prevalence among 42,831 individuals who participated in the JPHC next cohort, the details of which can be accessed at the website (<http://epi.ncc.go.jp/jphcnext/about/index.html>). A PRISMA 2009 Flow Diagram for study selection is presented in Fig. [1](#Fig1){ref-type="fig"}.Figure 1PRISMA flow chart of study selection.

Data extraction and quality assessment {#Sec5}
--------------------------------------

Two authors (LY and WC) independently searched and reviewed titles and abstracts identified by the literature search to select eligible studies. Citations identified by either reviewer were selected for full-text review. The same two authors then independently assessed the full-text articles, using predefined inclusion and exclusion criteria. Discrepancies were resolved by discussion and, if necessary, by the decision of a third author (KS). We extracted the prevalence by birth year from studies if such data were available in the original articles. And if such data were not available, we estimated birth year based on age groups and the year when the studies were conducted. The risk-of-bias assessment of all included studies was independently performed by two authors (LY and WC) using the Joanna Briggs Institute Prevalence Critical Appraisal Tool, in which 10 criteria are used to evaluate the methodological quality of studies that report prevalence data^[@CR8]^. The results of risk-of-bias assessment were summarized in the Supplementary Table [1](#MOESM1){ref-type="media"}.

Statistical analysis {#Sec6}
--------------------

Based on age groups reported in the original studies and the year when the studies were conducted, we converted them to birth years. For four studies which did not report the year of research, publication year was used instead to calculate the birth year^[@CR9]--[@CR12]^. For the analysis, we extracted data for the prevalence of *H*. *pylori* infection by birth year from each study: a total of 300 data points from 47 studies. In synthesizing the study results, we conducted a meta-regression to account for heterogeneity in the prevalence of *H*. *pylori* infection between studies using a logit link (logistic model).

The pre-specified explanatory variables included in the meta-regression were as follows: study ID, birth year, population source (community-based or clinical-based), diagnostic testing (serological test, or others; others include: urinary assay, salivary assay, stool antigen test, ^13^C-urea breath test and gastric biopsy), types of ELISA kits for measuring *H*. *pylori* positivity (antigen derived from domestic or foreign strains), and data collection period (prior to the year 2000, or later than 2000), with study ID as a random effect and other variables as fixed effects. Community samples came from nonclinical, population-based case-control or cross-sectional studies, and clinic-based samples included participants who were outpatients or underwent health check-ups in the clinical facilities. The year 2000 was chosen as a cutoff because the Japanese national health insurance scheme has covered *H*. *pylori* eradication for treating peptic ever since.

Since we have little prior justification for assuming a linear relationship between logit (the prevalence of *H*. *pylori* infection) and birth year, we used a penalized cubic spline to model the prevalence as a function of birth year in the framework of generalized additive mixed model (GAMM) implemented in the mgcv package in R^[@CR13]^.In this analysis, we weighted observations by the inverse of the sum of the within-study variance and the residual between-study variance using the meta package^[@CR14]^ in R. For all tests, *P* $\documentclass[12pt]{minimal}
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Subsequently, we performed sensitivity analyses stratified by study qualities (good or poor) which were defined according to the results of risk-of-bias diagnosis (studies that met higher or equal to 7 out of 10 criteria were defined as good quality, and the rest were defined as poor) or stratified by the year of research conducted (earlier or later than 2000), or by excluding children data points (n = 57) due to the concern that the accuracy of test kits in children has not been fully elucidated.

Results {#Sec7}
=======

The screening process is detailed in Fig. [1](#Fig1){ref-type="fig"}. Of the 86 full-text articles we reviewed, 46 met the inclusion criteria^[@CR4],[@CR5],[@CR9]--[@CR12],[@CR15]--[@CR54]^. Collectively these citations included in the present study spanned birth years starting in 1908 and ending in 2003. Table [1](#Tab1){ref-type="table"} presents the characteristics for each study. Collectively, we successfully included 170,752 adults in the meta-regression analysis. Most of the studies were cross-sectional studies and were conducted in health screening, outpatient, or community settings.Table 1Characteristics of studies addressing the prevalence of *H*. *pylori* infection in Japanese.Study IDReferenceData collection periodParticipantsSettingAdults or ChildrenRandom SamplingNMean Age \[range\]Specimen typeMeasurement kitAntigen from domestic or foreign strainsTested (n)Positive (n)Prevalence (%)1Fukao *et al*.^[@CR9]^NAHealthy blood donorsCommunityChildren & adultsNo1815\[16--64\]SerumELISA kit (QUIDEL Corp., San Diego)Foreign181594953.32Replogle *et al*.^[@CR39]^1980--1993Patients screened for Hepatitis B virus at Tokyo University HospitalClinical- or Hospital-basedChildren & adultsNo1494\[0--94\]SerumNANA120747038.93Kumagai *et al*.^[@CR28]^1986, 1994Participants of a cohort studyGeneral populationChildren & adultsNo641, 549\[6--80\]SerumGAP-IgG test (Biomerica, Newport Beach, CA)Foreign641, 549510, 37049.6, 67.44Youn *et al*.^[@CR54]^1993Patients without gastrointestinal symptomsClinical- or Hospital-basedChildren & adultsNo580\[2--6\], \[7--19\], \[20-\]SerumImmunoblot assayNA100, 260, 10020, 108, NA20, 40 \> 755Kikuchi *et al*.^[@CR26]^1996Public service workersCommunityAdultsNo5000\[19--69\]SerumPilika Plate G Helicobacter, II (Biomerica Ltd., Newport Beach, CA)Foreign4361133030.56Fujisawa *et al*.^[@CR21]^1974, 1984, 1994Participants in a health screening programCommunityChildren & adultsYes1015Median 35.6, \[0--89\]SerumGAP-IgG test (Biomerica, Newport Beach, CA)Foreign101542642.07Yang *et al*.^[@CR53]^1996Employees of a manufacturing plantCommunityAdultsNo598\[20--59\]SerumGAP-IgG test (Biomerica, Newport Beach, CA)Foreign54521639.68Shibata *et al*.^[@CR41]^1997ResidentsGeneral populationAdultsNo1207\[30--64\]SerumGAP-IgG, Biomerica, USAForeign63631048.79Ogihara *et al*.^[@CR36]^1989--1990Employees of small and medium-sized textile companiesCommunityAdultsNo9500\[39--65 + \]SerumPilika Plate G Helicobacter, II (Biomerica Ltd, Newport, USA)Foreign8837426848.310Yamagata *et al*.^[@CR50]^1988Participants of a cohort studyGeneral populationAdultsNo274257 in men, 59 in women, \[40--80 + \]SerumHM-CAP (Enteric Products Inc, Westbury, NY)Foreign2602172166.111Kurosawa *et al*.^[@CR29]^1995--1996Elementary/junior high School studentsCommunityChildrenNo6106 and 14 yearsSalivaHELISAI kitForeign6108313.612Okuda *et al*.^[@CR38]^1998--1999Asymptomatic childrenClinical- or Hospital-basedChildrenNo484\[0--12\]StoolMeridian Diagnositics, Cincinnati, USAForeign484316.413Yamaji *et al*.^[@CR51]^1996--1997Individuals attending a health screening programCommunityAdultsNo648948.1 \[NA\]SerumGAP-IgG test (Biomerica, Newport Beach, CA)Foreign5732269547.014Yamashita *et al*.^[@CR52]^1995--1996Healthy Children in an out-patient clinicClinical- or Hospital-basedChildrenNo336\[0--19\]SerumHEL-p-test; AMRAD, Melbourne, Victoria, AustraliaForeign3365917.515Shibata *et al*.^[@CR5]^1993Residents attending a health screening programGeneral populationAdultsNo2347\[30--79\]SerumHM-CAP, EPI Inc., USAForeign95470373.716Fukuda *et al*.^[@CR10]^2003Asymptomatic childrenGeneral populationChildrenNo3008SerumHEL-p-test; AMRAD, Melbourne, Victoria, AustraliaForeign3003712.317Kato *et al*.^[@CR11]^NAHealthy ChildrenClinical- or Hospital-basedChildrenNo4546.1\[0--15\]SerumHM-CAP and PP-CAP, En-teric Products, New York, NY, USAForeign4545512.218Kato *et al*. 2004NAIndividuals with upper, gastrointestinal symptomsClinical- or Hospital-basedAdultsNo6578\[21--71 + \]SerumHM-CAP, Enteric Products, Incorporated, Stony Brook, NY, USA or a GAP lgG kit (Bio-Rad, Richmond, CA, USA).Foreign6578330050.219Nobuta *et al*.^[@CR12]^1995--1996Asymptomatic individuals attending a health screening programCommunityAdultsNo250, 20940.7 (Niigata), 39.1 (Okinawa)SerumHM-CAPNA250, 209125, 8850.0, 41.120Kikuchi *et al*.^[@CR27]^1988--1990Residents in various areasGeneral populationAdultsNo635\[40--79\]SerumJ-HM-CAP, Kyowa Medex Co. Ltd., TokyoDomestic63344370.021Kawade *et al*.^[@CR24]^1999--2001Patients with dyspepsiaClinical- or Hospital-basedAdultsNo64482.7 \[65--107\]SerumNANA64433752.322Shimatani *et al*.^[@CR42]^1997--2003University students attending a health check-up programGeneral populationAdultsNo53023.7 \[NA\]Biopsy & serumRapid urease test (CLO test, Ballard Medical Products, Utah, USA), and HM-CAP Enteric Products, Westbury, NY, USA)Foreign5308716.423Sasazuki *et al*.^[@CR40]^1990--1992Participants of a cohort studyGeneral populationAdultsNo51157.4 \[NA\]SerumE Plate "Eiken" H. pylori, Antibody, Eiken Kagaku Co. Ltd., Tokyo, JapanDomestic51138374.924Fujimoto *et al*.^[@CR20]^1993, 2002Residents attending a health screening programGeneral populationAdultsNo3819\[20--70 + \]SerumELISA (JHM-CAP, Kyowa Medix Co.,Tokyo, Japan)Domestic3819211655.425Shiotani *et al*.^[@CR45]^2005--2006University studentsCommunityAdultsYes77719.5 \[18--25\]SerumE Plate test (Eiken Kagaku)Domestic77711414.726Naito *et al*.^[@CR31]^2002--2003Children from kindergarten or elementary school attending a health screening programCommunityChildrenNo4524, 7, 10UrineURINELISA H.pylori kit (Otsuka Pharmaceuticals, Tokyo)Domestic150, 150, 149, 149, 153, 1538, 10, 7, 6, 6, 75.3, 6.7, 4.7, 4.0, 4.0, 4.6Study IDReferenceData collection periodParticipantsSettingAdults or ChildrenRandom SamplingNMean Age \[range\]Specimen typeMeasurement kitAntigen from domestic or foreign strainsTested (n)Positive (n)Prevalence (%)27Hirai *et al*.^[@CR16]^2007Asymptomatic adultsClinic- or Hospital-basedAdultsNo235\[40--63\]StoolTestMate Papid Pylori Antigen; BD JapanDomestic1867540.328Mizuno *et al*.^[@CR30]^1987ResidentsGeneral populationAdultsNo2589\[35--75 + \]SerumPilika Plate G Helicobacter, II (Biomerica Ltd., Newport Beach, CA)Foreign2859214775.129Nakajima *et al*.^[@CR32]^1998, 2005Individuals attending a health screening programCommunityAdultsNo384\[20--79\]SerumE-plate (Eiken Chemical, Tokyo, Japan)Domestic38419250.030Kawai *et al*.^[@CR25]^2003--2004Patients undergoing routine health check-upClinic- or Hospital-basedAdultsNo41839.2 \[22--58\]SerumE-plate (Eiken Chemical, Tokyo, Japan)Domestic41814133.731Nakao *et al*.^[@CR33]^2001--2005All first-visit outpatients at Aichi Cancer CenterClinic- or Hospital-basedAdultsNo1465\[20--79\]SerumE-plate (Eiken Chemical, Tokyo, Japan)Domestic140679856.832Akamatsu *et al*.^[@CR15]^2007--2009Junior high school studentsGeneral populationChildrenNo1232\[16--17\]UrineRAPIRAN Otsuka Pharmaceutical Co, Tokyo, JapanDomestic1224645.233Toyoda *et al*.^[@CR47]^2004--2007ResidentsGeneral populationAdultsNo172857.8 \[30--89\]SerumJHM-CAP, Kyowa, Medex Co., Ltd., Tokyo, JapanDomestic154092359.934Tamura *et al*.^[@CR46]^2008--2010Participants of a cohort studyGeneral populationAdultsNo5167\[35--69\]UrineRapiran (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan)Domestic5167188136.435Shimoyama *et al*.^[@CR43]^2005Healthy adults attending a health screening programGeneral populationAdultsNo1048\[25--85\]SerumE-plate (Eiken Chemical, Tokyo, Japan)Domestic104863860.936Urita *et al*.^[@CR48]^1999--2004Children attending a clinicClinic- or Hospital-basedChildrenNo83812.4 \[1--18\]SerumNANA82810112.137Nakagawa *et al*.^[@CR17]^2005--2010Healthy adults attending a clinicClinic- or Hospital-basedAdultsNo268\[20--78\]UBTNANA26817565.338Ueda *et al*.^[@CR67]^1997--2013Individuals attending a health screening programCommunityAdultsNo14716NA \[20 + \]Serum/ur-ine/stoolE-plate (Eiken H.pylori antibody)Domestic14716587939.939Hirayama *et al*.^[@CR4]^2008Employees of a large companyCommunityAdultsNo21144NA \[35--79\]SerumE-plate (Eiken Chemical Co.Ltd, Tokyo, Japan)Domestic21144582227.540Okuda *et al*. 20142010--2011Participants of a population-based surveyGeneral populationChildrenNo1299, 1909NA \[0--8\], NA \[0--11\]StoolTestMate Pylori Antigen EIA (Wakamoto Pharmaceutical Co. Ltd)Domestic688, 83513, 151.9, 1.841Shimoyama *et al*.^[@CR44]^2012Healthy adults attending a health surveyGeneral populationAdultsNo810\[40--80\]Serum/st-oolE-plate (Eiken Chemical Co.jLtd, Tokyo, Japan; Testmate EIA (Wakamoto Pharmaceutical Co., Ltd, Kyowa Medex)Domestic50522444.442Watanabe *et al*.^[@CR49]^2005--2013All first-visit outpatients at Aichi Cancer CenterClinic- or Hospital-basedAdultsNo469860.5 \[20--79\]SerumE-plate (Eiken H.pylori antibody)Domestic4285160737.543Kamada *et al*.^[@CR23]^1975--1978, 1991--1994, 2010--2013Patients undergoing endoscopy for dyspepsia or gastric cancer screeningClinic- or Hospital-basedAdultsNo1381\[18--70 + \]BiopsyGiemsa or Gimenez stainingNA289, 787, 305216, 417, 10774.7, 53.0, 35.144Akamatsu *et al*.^[@CR18]^2007--2013High school studentsGeneral populationChildrenNo3251\[16--17\]UrineRAPIRAN Otsuka Pharmaceutical Co, Tokyo, JapanDomestic32511364.245Nakayama *et al*. 2016^[@CR34]^2011--2013Junior high school studentsGeneral populationChildrenNo681NA \[12--15\]SerumE-plate (Eiken Chemicals, Tokyo, Japan)Domestic454143.146Charvat *et al*.^[@CR19]^, JPHC Cohort II1993--1994Residents in various areasGeneral populationAdultsYes21682\[30--79\]SerumE-plate (Eiken Chemicals, Tokyo, Japan)Domestic216821480968.3Abbreviation: NA, Not available; UBT, ^13^C-urea breath test.Information on JPHC next cohort (Study ID = 45) is unpublished, details available upon request.

At first, full GAMM model with all of the aforementioned potential covariates included (Model 1) was estimated. To confirm whether Model 1 could best fit our data set, two more models were also estimated: one with covariates that showed significant effects in Model 1 (Model 2); the other one with only penalized cubic spline function of birth year and the random effect function of study ID (Model 3). Table [2](#Tab2){ref-type="table"} summarizes Akaike's information criterion (AIC) and Bayesian information criterion (BIC) values for all the models. Comparison of AIC and BIC showed that the full model we proposed initially (Model 1) was the best one to fit the data (Table [2](#Tab2){ref-type="table"}, **Model 1**, 1687.895 and 1880.004, respectively). Thus, Model 1 was believed to be appropriate to further predict the prevalence of *H*. *pylori* according to birth year in Japanese. The results of fitting for the best GAMM model (Model 1) are shown in Table [3](#Tab3){ref-type="table"}. A borderline significant effect of diagnostic test (*P* = 0.08) is suggested, while non-significant effects of source of population, types of ELISA kit, or research year is identified.Table 2Information for tested models.AICBICLogLikModel 1:Logit(P) = s(birth year) + r(study ID) + f(source of population) + f(diagnostic test) + f(ELISA kits) + f(research year)1687.8951880.004792.0792 (df = 51.87)Model 2:Logit(P) = s(birth year) + r(study ID) + f(diagnostic test)1702.2571889.008−800.7071 (df = 50.42)Model 3:Logit(P) = s(birth year) + r(study ID)1702.9361890.291−800.8835 (df = 50.58)Abbreviations and definitions:AIC: Akaike's information criterion;BIC: Bayesian information criterion;LogLik: Log-likelihood;P: prevalence;s: penalized cubic spline;r: random effect;f: fixed effect;df: degree of freedom. Table 3Summary statistics from fitting meta-regression in the best model.*Fixed effect parameter estimates*:VariablesOR (95% CI)*P*Source of population Community-based1 Clinical-based1.12 (0.73--1.52)0.56Diagnostic test Serology1 Others\*0.73 (0.37--1.08)0.08ELISA kits Domestic1 Foreign1.15 (0.82--1.49)0.41Research year Earlier than 20001 Later than 20000.89 (0.59--1.19)0.43***Approximated significance of smooth terms:*Estimated degree of freedomReference degree of freedomChi square*P*** Birth year7.38.14048\<0.00001***Random effect parameter estimates***: Study ID37.241.01881\<0.00001\*Others include: urinary assay, salivary assay, stool antigen test,^13^C-urea breath test, and gastric biopsy.

The results also demonstrate that the smoothing trend in birth year is significant (*P* $\documentclass[12pt]{minimal}
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                \begin{document}$$ < $$\end{document}$ 0.00001). This decreasing trend is illustrated in Fig. [2](#Fig2){ref-type="fig"}, which depicts the smoothed curve of the relationship between *H*. *pylori* infection prevalence and birth year. The spline function estimate of prevalence indicates that the prevalence of *H*. *pylori* ranged between 50% and 70% during the first four decades (1908--1948), after which the prevalence began to decrease steadily until 2003. To be specific, the predicted prevalence (%, 95% CI) was 60.9 (56.3--65.4), 65.9 (63.9--67.9), 67.4 (66.0--68.7), 64.1 (63.1--65.1), 59.1 (58.2--60.0), 49.1 (49.0--49.2), 34.9 (34.0--35.8), 24.6 (23.5--25.8), 15.6 (14.0--17.3), and 6.6 (4.8--8.9) among those who were born in the year 1910, 1920, 1930, 1940, 1950, 1960, 1970, 1980, 1990, and 2000, respectively. The most recent cohorts, those born after 1998, appear to have a prevalence as low as less than 10% (Table [4](#Tab4){ref-type="table"}).Figure 2Multivariable adjusted prevalence of *H*. *pylori* infection in Japanese by birth year from year of 1908--2003. Table 4Predicted prevalence of *H*.*pylori* infection in Japanese population by birth year from 1908 to 2003.Birth YearPredicted Prevalence95% Confidence Intervals190859.7%54.3%64.9%190960.3%55.3%65.1%191060.9%56.3%65.4%191161.5%57.3%65.6%191262.1%58.2%65.8%191362.7%59.1%66.1%191463.2%60.0%66.3%191563.7%60.8%66.6%191664.2%61.5%66.8%191764.7%62.2%67.1%191865.1%62.8%67.4%191965.6%63.4%67.6%192065.9%63.9%67.9%192166.3%64.4%68.2%192266.6%64.7%68.4%192366.9%65.1%68.6%192467.1%65.3%68.8%192567.3%65.6%68.9%192667.4%65.7%69.0%192767.5%65.9%69.0%192867.5%66.0%69.0%192967.5%66.0%68.8%193067.4%66.0%68.7%193167.3%66.0%68.5%193267.1%65.9%68.3%193366.9%65.7%68.0%193466.6%65.5%67.7%193566.3%65.2%67.4%193665.9%64.8%67.0%193765.5%64.4%66.6%193865.1%64.0%66.1%193964.6%63.5%65.6%194064.1%63.1%65.1%194163.6%62.5%64.5%194263.0%62.0%64.0%194362.5%61.5%63.4%194461.9%60.9%62.9%194561.4%60.4%62.4%194660.8%59.8%61.9%194760.4%59.3%61.4%194859.9%58.9%60.9%194959.5%58.5%60.4%195059.1%58.2%60.0%195158.6%57.8%59.5%195257.2%56.5%57.8%195356.6%55.9%57.2%195455.8%55.2%56.4%195555.0%54.5%55.5%195654.0%53.6%54.5%195753.0%52.6%53.3%195851.8%51.5%52.0%195950.5%50.4%50.5%196049.1%49.0%49.2%196147.7%47.4%47.9%196246.2%45.8%46.6%196344.7%44.2%45.2%196443.2%42.6%43.8%196541.7%41.0%42.4%196640.3%39.6%41.0%196738.9%38.1%39.6%196837.5%36.7%38.3%196936.2%35.4%37.0%197034.9%34.0%35.8%197133.7%32.7%34.6%197232.5%31.4%33.5%197331.3%30.2%32.5%197430.3%29.1%31.4%197529.2%28.0%30.4%197628.2%27.1%29.4%197727.3%26.1%28.5%197826.4%25.2%27.5%197925.5%24.4%26.6%198024.6%23.5%25.8%198123.7%22.5%25.0%198222.9%21.6%24.1%198322.0%20.7%23.3%198421.1%19.7%22.5%198520.2%18.8%21.7%198619.3%17.8%20.8%198718.3%16.9%19.9%198817.4%15.9%19.0%198916.5%14.9%18.2%199015.6%14.0%17.3%199114.7%13.0%16.5%199213.8%12.1%15.7%199313.0%11.3%14.9%199412.2%10.4%14.1%199511.4%9.7%13.4%199610.7%8.9%12.7%19978.1%6.4%10.2%19987.6%5.8%9.8%19997.0%5.3%9.3%20006.6%4.8%8.9%20016.1%4.3%8.5%20025.7%3.9%8.2%20035.3%3.5%7.8%

Further sensitivity analyses yielded essentially similar results, which were presented as figures in supplement materials (Supplementary Figures [1](#MOESM1){ref-type="media"}--[5](#MOESM1){ref-type="media"}).

Discussion {#Sec8}
==========

To our knowledge, this is the first attempt to delineate the prevalence of *H*. *pylori* infection by birth year among the Japanese population based on systematic review and meta-regression analysis. Our findings suggest that *H*. *pylori* infection exhibits a birth cohort effect in Japan, with prevalence decreasing steadily in individuals born in successive years, from 59.1**%** in 1950 to 15.6**%** in 1990. In particular, the prevalence among children and adolescents is declining to very low levels, with the multivariable adjusted prevalence lower than 10% for individuals who were born after the year 1998. The multivariable adjusted prevalence of *H*. *pylori* infection seems to be lower among the older cohorts (subjects born during 1908--1918) compared with relatively younger subjects (birth year between 1923--1933) in Fig. [2](#Fig2){ref-type="fig"}. The possible reasons include potential development of atrophy or unstable estimates due to small sample sizes (the 95% CIs are much wider) among the older cohorts. Therefore, the uncertainty in prevalence estimates may exist and a cautious interpretation of results of the older cohorts is needed.

After evaluating various tools for assessing the quality of observational studies^[@CR55]^, we adopted the Joanna Briggs Institute Prevalence Critical Appraisal Tool^[@CR56]^, which was developed exclusively for epidemiological studies that reported on prevalence or incidence. It should be noted that even guided by such a tool, the risk-of-bias assessment is a subjective exercise. For this reason, two authors evaluated the risk-of-bias for each study independently, with disagreement resolved by either discussion or by a third author. Several concerns over methodological quality have arisen in the risk of bias assessment. First, concerning sampling strategy, most studies included in the current systematic review did not specify sampling strategy, which might have influenced the prevalence estimates owing to possible sampling bias. Second, because most studies did not explain the reasons for non-participation, it is not clear whether the study population was representative of the target population. If many individuals opted out of the survey because of illness or perceived good health, results may be an underestimate or overestimate of the real prevalence in the population. Third, serological antibody tests were used to define *H*. *pylori* infection in the majority of studies. A combination of at least two diagnostic methods is recommended to increase the validity of results, but only two studies adopted multiple tests to make a definitive diagnosis^[@CR42],[@CR44]^. Fourth, controlling for two important confounders, *H*. *pylori* eradication and gastric atrophy, was not addressed in most studies. Taken together, the varied methodological approaches in the included studies and the above-mentioned limitations may have contributed to the wide variation in prevalence estimates for *H*. *pylori* infection, resulting in high between-study heterogeneity.

Based on various prevalence estimates for various age groups in included studies, a clear birth-cohort pattern emerged from our analysis. The prevalence of *H*. *pylori* infection was lower in sequential birth cohorts of Japanese born from 1908 to 2003. The results of our meta-analysis corroborated the birth-cohort pattern for *H*. *pylori* infection that was demonstrated in several included studies^[@CR4],[@CR49]^, as well as a recent study exploring age, period, and cohort effects on gastric cancer mortality^[@CR57]^. Moreover, our finding of a birth-cohort pattern for *H*. *pylori* infection in Japanese is similar to that documented in the United States and China, although the trajectory of decline across birth cohorts differed in these three countries^[@CR58],[@CR59]^. The prevalence estimates observed for recent, younger birth cohorts in our study were comparable to those reported in the Western countries, but they were even lower when compared with those reported in China and South Korea^[@CR60],[@CR61]^, two East Asian countries shouldering a similarly high gastric cancer burden. Whether the prevalence among young birth cohorts in Japan will continue to decline or it has already reached a nadir remains to be elucidated, although studies in Europe suggest that the prevalence has reached a nadir among children in recent years^[@CR62]^.

Of covariates included in the meta-regression, the birth year explains much of the heterogeneity across studies. In other words, the birth year exerts a strong influence on *H*. *pylori* prevalence. Diagnostic testing (serological tests or others) might also contribute to between-study heterogeneity. Despite the sub-optimal performance characteristics of serological tests when compared with other diagnostic tests such as the urea breath test, the vast majority of included studies used serological tests to diagnose *H*. *pylori* infection because it is easy to perform and has good negative predictive value. In general, as the prevalence of an infection falls in a community, the accuracy of serological tests suffers, with an increase in the proportion of false-positive results. This also applies to *H*. *pylori* infection and this caveat should be considered when serological tests are used to diagnose *H*. *pylori* infection in a young population with a much-declined prevalence. Other potential explanations for false-positive serological test results include cross reactivity with other antigens, recent seroconversion and laboratory error. On the other hand, serological ELISA test might yield false-negative results in individuals who had serotiters in the range of 3--10 U/mL. Therefore, the observed prevalence reflected a mix of effects from both false-positive and false-negative results, making it difficult to quantify the true prevalence in the population. Because the vast majority of previous studies were limited by adopting only one diagnostic test, a combination of serological tests and other tests is necessary to increase the accuracy of the diagnosis. In addition, our meta-regression analysis indicated that differences in antigens used in ELISA did not significantly contribute to the between-study heterogeneity (odds ratio of foreign vs. domestic: 1.15, 95% CI: 0.82--1.49, *p* = 0.41). There was a concern that accuracy of kits made in Western countries may yield more intermediate results for Japanese people when compared with kits using antigens isolated from Japanese strains (for example, E-plate). However, according to our previous study^[@CR63]^, when the recommended cut-off was used, there were no significant differences in diagnostic accuracy (95% CI) (domestic vs. imported: 92.5%, 90%-95% vs. 91.2%, 89%-94%, p $\documentclass[12pt]{minimal}
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                \begin{document}$$ > $$\end{document}$ 0.05), which is also in line with our current finding. With the predominant use of E-plate in recent years, the differences in prevalence stemming from antigen differences should not be a serious concern.

Our study has several limitations. First, including only English-language articles may lead to an over- or underestimation of the results. However, we only identified a very limited number of Japanese-language articles, which are mostly narrative reviews or conference reports. Nevertheless, no systematic bias from the use of language restriction (English-restriction) was noted in systematic review and meta-analysis^[@CR64]^. In addition, another study^[@CR65]^ found that English-language papers were of higher methodological quality than papers published in languages other than English. Thus, we believe that excluding studies published in Japanese language in the present study has little effect on summary estimates of prevalence of *H*. *pylori* infection. Second, because the modeling of prevalence estimates by birth cohorts across studies was used in the present meta-analysis, we were not able to assess traditional publication bias. Third, high-quality data for estimating the prevalence of *H*. *pylori* infection in the general Japanese population are limited. In addition, regarding the covariates included in the present meta-regression analysis, the data were lacking on other *H*. *pylori* infection-related factors, such as socioeconomic status, living conditions, and personal hygiene habits. These factors may have also contributed to the declining trend of *H*. *pylori* infection prevalence in Japan. Fourth, *H*. *pylori* is characterized by its genetic diversity. Its virulence factors, such as CagA and VacA, vary geographically^[@CR66]^. The effect of *H*. *pylori* genetic diversity on the changes in prevalence of *H*. *pylori* infection needs further study. Finally, although study showed that serological tests could be useful for children^[@CR67]^, the accuracy of this kit in children has not yet been fully elucidated. Thus, studies that included or targeted children may generate uncertain estimates. However, excluding extracted children data points (n = 57) from the complete data set did not change the results materially (Supplementary Figure [5](#MOESM1){ref-type="media"}).

In conclusion, our study demonstrated a birth-cohort pattern of *H*. *pylori* infection among the Japanese population. Given the fact that the birth-cohort pattern of *H*. *pylori* shapes the trends of gastric cancer over time, our findings help to inform screening efforts aimed at prevention and early detection of gastric cancer in Japan. The decreased prevalence of *H*. *pylori* infection in successive generations should be weighed in gastric cancer screening programs.
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